Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
108 studies found for:    Open Studies | "Amyloidosis"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Amyloidosis"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Institutional Registry of Amyloidosis
Condition: Amyloidosis
Intervention:
2 Not yet recruiting A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
Condition: Amyloidosis
Interventions: Drug: Carfilzomib;   Drug: Thalidomide;   Drug: Dexamethasone
3 Recruiting Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
Condition: Amyloidosis
Intervention: Drug: Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4
4 Recruiting Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis
Condition: Amyloidosis
Intervention: Drug: Idelalisib
5 Recruiting Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis
Condition: Amyloidosis
Interventions: Other: blood collection;   Other: bone marrow collection
6 Not yet recruiting A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis
Condition: Amyloidosis
Intervention: Drug: GSK3039294
7 Recruiting Oral Doxycycline Administered as an Adjunct to Plasma Cell Directed Therapy in Light Chain Amyloidosis
Condition: Primary Systemic Amyloidosis
Intervention: Drug: Doxycycline
8 Recruiting Body Composition in Systemic Amyloidosis
Condition: Amyloidosis
Intervention: Other: Dietary advice
9 Recruiting Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography
Condition: Cardiac Amyloidosis
Intervention: Drug: F-18 florbetapir PET
10 Recruiting Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis
Condition: Amyloidosis
Intervention: Drug: Daratumumab
11 Recruiting Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis
Condition: Cardiac Amyloidosis
Intervention:
12 Recruiting Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis
Condition: Primary Amyloidosis of Light Chain Type
Interventions: Drug: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias);   Drug: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG
13 Recruiting The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
Condition: AL Amyloidosis
Interventions: Drug: NEOD001;   Drug: Placebo
14 Not yet recruiting Daratumumab for the Treatment of Patients With AL Amyloidosis
Condition: AL Amyloidosis
Intervention: Drug: daratumumab
15 Recruiting Post Approval Study of Lixelle for the Treament of Dialysis-Related Amyloidosis
Condition: Dialysis Amyloidosis
Intervention: Device: Lixelle® treatment
16 Recruiting Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis
Condition: Cardiac Amyloidosis
Interventions: Drug: Thalidomide;   Drug: Dexamethasone
17 Recruiting Transthyretin-Associated Amyloidoses Outcome Survey (THAOS)
Conditions: Transthyretin Mutations;   Transthyretin Amyloidosis
Intervention: Other: None. Observational Study.
18 Recruiting Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis
Conditions: Amyloidosis;   Primary Amyloidosis
Intervention:
19 Recruiting A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)
Conditions: Light Chain (AL) Amyloidosis;   Cardiac Involvement
Interventions: Drug: Epigallocatechin-3-gallate (EGCG);   Drug: Placebo
20 Recruiting Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Condition: Relapsed or Refractory Systemic Light Chain Amyloidosis
Interventions: Drug: IXAZOMIB;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Cyclophosphamide;   Drug: Thalidomide;   Drug: Lenalidomide

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.